HomeCompareICVX vs XYLD

ICVX vs XYLD: Dividend Comparison 2026

ICVX yields 13.06% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ICVX wins by $22.0K in total portfolio value
10 years
ICVX
ICVX
● Live price
13.06%
Share price
$15.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.3K
Annual income
$2,943.04
Full ICVX calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — ICVX vs XYLD

📍 ICVX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodICVXXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ICVX + XYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ICVX pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ICVX
Annual income on $10K today (after 15% tax)
$1,110.39/yr
After 10yr DRIP, annual income (after tax)
$2,501.58/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, XYLD beats the other by $234.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ICVX + XYLD for your $10,000?

ICVX: 50%XYLD: 50%
100% XYLD50/50100% ICVX
Portfolio after 10yr
$36.3K
Annual income
$3,081.03/yr
Blended yield
8.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ICVX right now

ICVX
Analyst Ratings
5
Buy
1
Hold
Consensus: Buy
Price Target
$27.00
+76.4% upside vs current
Range: $27.00 — $27.00
Altman Z
22.6
Piotroski
3/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ICVX buys
0
XYLD buys
0
No recent congressional trades found for ICVX or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricICVXXYLD
Forward yield13.06%10.98%
Annual dividend / share$2.00$4.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$47.3K$25.3K
Annual income after 10y$2,943.04$3,219.02
Total dividends collected$21.0K$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ICVX vs XYLD ($10,000, DRIP)

YearICVX PortfolioICVX Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$12,006$1,306.34$10,818$1,098.39+$1.2KICVX
2$14,313$1,465.82$11,738$1,222.51+$2.6KICVX
3$16,948$1,633.07$12,774$1,364.64+$4.2KICVX
4$19,941$1,807.22$13,944$1,527.86+$6.0KICVX
5$23,324$1,987.33$15,270$1,715.87+$8.1KICVX
6$27,129$2,172.42$16,775$1,933.09+$10.4KICVX
7$31,390$2,361.53$18,490$2,184.87+$12.9KICVX
8$36,141$2,553.64$20,450$2,477.63+$15.7KICVX
9$41,419$2,747.79$22,697$2,819.19+$18.7KICVX
10$47,261$2,943.04$25,280$3,219.02+$22.0KICVX

ICVX vs XYLD: Complete Analysis 2026

ICVXStock

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.

Full ICVX Calculator →

XYLDETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this ICVX vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ICVX vs SCHDICVX vs JEPIICVX vs OICVX vs KOICVX vs MAINICVX vs QYLDICVX vs JEPQICVX vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.